NCT07415005 2026-02-17
Lorlatinib Plus Local Consolidation Therapy In ALK Positive Advanced Non-Small Cell Lung Cancer
M.D. Anderson Cancer Center
Phase 2 Not yet recruiting
Clinical Trials
18 trialsNCT05785767 2026-01-22
A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC)
Regeneron Pharmaceuticals
Phase 2/3 Active not recruiting
NCT07105176 2025-08-19
HS-IT101 Injection for Advanced NSCLC
Qingdao Sino-Cell Biomedicine Co., Ltd.
Phase 1 Not yet recruiting
NCT06980272 2025-06-24
SSGJ-707 in Advanced Non-Small Cell Lung Cancer
Shenyang Sunshine Pharmaceutical Co., LTD.
Phase 3 Recruiting
NCT05504278 2025-01-27
Efficacy and Safety of IBI351 in Combination With Chemotherapy in Advanced Non-squamous Non-small Cell Lung Cancer Subjects With KRAS G12C Mutation
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1 Recruiting
NCT04541706 2024-12-20
Lorlatinib in ALK Inhibitor Treated Unresectable Advanced/Recurrent ALK-Positive Non Small Cell Lung Cancer Patients in India
Pfizer
Phase 4 Completed
NCT00652561 2024-09-03
Phase 2 Study of S-1 as 2nd Line Therapy in Advanced Non-Small Cell Lung Cancer
Taiho Oncology, Inc.
Phase 2 Completed
NCT04922658 2024-07-31
Surufatinib or Surufatinib Combined With Vinorelbine for Non-Small Cell Lung Cancer
Affiliated Cancer Hospital & Institute of Guangzhou Medical University
Phase 2 Unknown
NCT05978401 2023-08-07
Safety, Tolerability, and Efficacy of GLS-012 and GLS-010 in Patients With Advanced Non-Small Cell Lung Cancer
Guangzhou Gloria Biosciences Co., Ltd.
Phase 1/2 Not yet recruiting
NCT05287386 2022-03-18
A Single-Arm Phase II Clinical Study of Pemigatinib in the Treatment of Advanced Non-Small Cell Lung Cancer Patients With FGFR Alterations Who Have Failed Standard Therapy
The First Affiliated Hospital of Xiamen University
Phase 2 Unknown
NCT00345059 2016-01-14
DISTAL-2
National Cancer Institute, Naples
Phase 3 Terminated
NCT00983047 2015-08-27
Nimotuzumab Plus Docetaxel in Chemotherapy-Refractory/Resistant Patients With Advanced Non-Small-Cell Lung Cancer
Biotech Pharmaceutical Co., Ltd.
Phase 2 Terminated
NCT00330746 2012-05-18
CALC-1
National Cancer Institute, Naples
Phase 2 Completed
NCT00783471 2010-06-16
DOPERLO
Hellenic Cooperative Oncology Group
Phase 2 Terminated
NCT00786331 2009-08-03
Pemetrexed +/- Carboplatin as Second Line Treatment in NSCLC
Gruppo Oncologico Italiano di Ricerca Clinica
Phase 2 Unknown
NCT00161278 2008-07-30
Pilot Study for the Determination of Tumor Response to Chemotherapy in Advanced NSCLC Through Gene Expression Profiling
University of Michigan Rogel Cancer Center
Phase 2 Terminated
NCT00319514 2008-03-12
Weekly Versus 3-Weekly Docetaxel Plus Cisplatin for Advanced NSCLC
Gachon University Gil Medical Center
Phase 2 Completed
NCT00064636 2005-06-24
Phase I Dose Escalation Study of VELCADE Plus Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors
Millennium Pharmaceuticals, Inc.
Phase 1 Terminated